{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T01:43:31Z","timestamp":1769910211653,"version":"3.49.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>In spite of its relevance, treatments for the cancer anorexia and cachexia syndrome (CACS) are not available. One of the agents that recently reached phase III clinical trials is anamorelin. Its development, along with that of other agents for this indication, will be reviewed here, with a focus on the gaps in the current knowledge and future directions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>In spite of several targets showing promising results in early development, their difficulties obtaining regulatory approval underscore the need to reconsider the current strategies in drug development and the challenges in the field of CACS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Further research is needed in order to meet the challenges of developing treatments for CACS. Preclinical studies should expand our understanding about key regulators of appetite, muscle, and energy metabolism in this setting using models that can be translated reliably to humans. Clinical research efforts should focus on validating the entry criteria, endpoints, outcomes, and the potential synergistic effects and interaction between different targets, nutrition, and exercise interventions. Clinical meaningfulness and significance should be taken into account in the design of clinical trials. It is essential that all key stakeholders are included in the design of future strategies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/spc.0000000000000299","type":"journal-article","created":{"date-parts":[[2017,9,28]],"date-time":"2017-09-28T23:23:42Z","timestamp":1506641022000},"page":"266-271","source":"Crossref","is-referenced-by-count":19,"title":["What is next after anamorelin?"],"prefix":"10.1097","volume":"11","author":[{"given":"Jose M.","family":"Garcia","sequence":"first","affiliation":[{"name":"Geriatric Research, Education and Clinical Center (GRECC), VA Puget Sound Healthcare System"},{"name":"Department of Medicine, Division of Gerontology & Geriatric Medicine, University of Washington School of Medicine, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230926","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"R2-20230926","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0149-2918(05)80001-3","article-title":"Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern cooperative oncology group","volume":"69","author":"Dewys","year":"1980","journal-title":"Am J Med"},{"key":"R3-20230926","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/archinte.1988.00380070082020","article-title":"Clinical symptoms and length of survival in patients with terminal cancer","volume":"148","author":"Reuben","year":"1988","journal-title":"Arch Intern Med"},{"key":"R4-20230926","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0885-3924(98)00146-8","article-title":"Successful validation of the palliative prognostic score in terminally ill cancer patients. Italian multicenter study group on palliative care","volume":"17","author":"Maltoni","year":"1999","journal-title":"J Pain Symptom Manage"},{"key":"R5-20230926","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","article-title":"Cancer cachexia: mediators, signaling, and metabolic pathways","volume":"16","author":"Fearon","year":"2012","journal-title":"Cell Metab"},{"key":"R6-20230926","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(13)70055-X","article-title":"Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial","volume":"14","author":"Dobs","year":"2013","journal-title":"Lancet Oncol"},{"key":"R7-20230926","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.12-5-594","article-title":"Effect on body weight and safety of rc-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase i, randomized, placebo-controlled, multiple-dose study in healthy volunteers","volume":"12","author":"Garcia","year":"2007","journal-title":"Oncologist"},{"key":"R8-20230926","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ghir.2008.12.003","article-title":"Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers","volume":"19","author":"Garcia","year":"2009","journal-title":"Growth Horm IGF Res"},{"key":"R9-20230926","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1470-2045(14)71154-4","article-title":"Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials","volume":"16","author":"Garcia","year":"2015","journal-title":"Lancet Oncol"},{"key":"R10-20230926","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1470-2045(14)70155-X","article-title":"MABp1, a first-in-class true human antibody targeting interleukin-1alpha in refractory cancers: an open-label, phase 1 dose-escalation and expansion study","volume":"15","author":"Hong","year":"2014","journal-title":"Lancet Oncol"},{"key":"R11-20230926","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11912-017-0562-0","article-title":"Update on management of cancer-related cachexia","volume":"19","author":"Anderson","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"R12-20230926","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","article-title":"Anamorelin in patients with nonsmall-cell lung cancer and cachexia (romana 1 and romana 2): results from two randomised, double-blind, phase 3 trials","volume":"17","author":"Temel","year":"2016","journal-title":"Lancet Oncol"},{"key":"R13-20230926","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1470-2045(17)30006-2","article-title":"MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study","volume":"18","author":"Hickish","year":"2017","journal-title":"Lancet Oncol"},{"key":"R14-20230926","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/45230","article-title":"Ghrelin is a growth-hormone-releasing acylated peptide from stomach","volume":"402","author":"Kojima","year":"1999","journal-title":"Nature"},{"key":"R15-20230926","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1210\/en.2007-0271","article-title":"Characterization of adult ghrelin and ghrelin receptor knockout mice under positive and negative energy balance","volume":"149","author":"Sun","year":"2008","journal-title":"Endocrinology"},{"key":"R16-20230926","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1126\/science.276.5319.1706","article-title":"Essential role of growth hormone in ischemia-induced retinal neovascularization","volume":"276","author":"Smith","year":"1997","journal-title":"Science"},{"key":"R17-20230926","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1210\/en.2007-0828","article-title":"Ghrelin prevents cisplatin-induced mechanical hyperalgesia and cachexia","volume":"149","author":"Garcia","year":"2008","journal-title":"Endocrinology"},{"key":"R18-20230926","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/jcsm.12023","article-title":"Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved","volume":"6","author":"Chen","year":"2015","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R19-20230926","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/nmo.12098","article-title":"Intravenous ghrelin accelerates postoperative gastric emptying and time to first bowel movement in humans","volume":"25","author":"Falken","year":"2013","journal-title":"Neurogastroenterol Motil"},{"key":"R20-20230926","first-page":"320","article-title":"Mk-0677, an orally active growth hormone secretagogue reverses diet-induced catabolism","volume":"83","author":"Murphy","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"R21-20230926","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bbalip.2011.03.001","article-title":"Acylated and unacylated ghrelin attenuate isoproterenol-induced lipolysis in isolated rat visceral adipocytes through activation of phosphoinositide 3-kinase gamma and phosphodiesterase 3b","volume":"1811","author":"Baragli","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"R22-20230926","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1210\/jc.2013-1157","article-title":"Macimorelin (aezs-130)-stimulated growth hormone (GH) test: validation of a novel oral stimulation test for the diagnosis of adult GH deficiency","volume":"98","author":"Garcia","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R23-20230926","first-page":"611","article-title":"Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice","volume":"123","author":"Porporato","year":"2013","journal-title":"J Clin Invest"},{"key":"R24-20230926","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2265.2008.03321.x","article-title":"Ghrelin and the differential regulation of des-acyl (DSG) and oct-anoyl ghrelin (OTG) in human adipose tissue (AT)","volume":"70","author":"Kos","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R25-20230926","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1002\/cncr.27430","article-title":"Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study","volume":"118","author":"Hiura","year":"2012","journal-title":"Cancer"},{"key":"R26-20230926","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1210\/jc.2003-031768","article-title":"Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial","volume":"89","author":"Neary","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R27-20230926","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/sj.bjc.6604148","article-title":"Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia\/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study","volume":"98","author":"Strasser","year":"2008","journal-title":"Br J Cancer"},{"key":"R28-20230926","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00520-012-1500-1","article-title":"Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study","volume":"21","author":"Garcia","year":"2013","journal-title":"Support Care Cancer"},{"key":"R32-20230926","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.lungcan.2009.06.020","article-title":"A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and\/or poor performance nonsmall cell lung cancer patients (n01c9)","volume":"68","author":"Jatoi","year":"2010","journal-title":"Lung Cancer"},{"key":"R33-20230926","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/MPA.0b013e318279b87f","article-title":"Disrupting cytokine signaling in pancreatic cancer: a phase i\/ii study of etanercept in combination with gemcitabine in patients with advanced disease","volume":"42","author":"Wu","year":"2013","journal-title":"Pancreas"},{"key":"R34-20230926","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/jcsm.12083","article-title":"Request for regulatory guidance for cancer cachexia intervention trials","volume":"6","author":"Fearon","year":"2015","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R35-20230926","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0885-3924(94)00117-4","article-title":"Dronabinol as a treatment for anorexia associated with weight loss in patients with aids","volume":"10","author":"Beal","year":"1995","journal-title":"J Pain Symptom Manage"},{"key":"R36-20230926","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/00000421-198504000-00006","article-title":"THC or Compazine for the cancer chemotherapy patient - the UCLA study. Part ii: patient drug preference","volume":"8","author":"Ungerleider","year":"1985","journal-title":"Am J Clin Oncol"},{"key":"R37-20230926","doi-asserted-by":"crossref","DOI":"10.1002\/jcsm.12201","article-title":"A randomized phase ii feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer","author":"Solheim","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R38-20230926","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/jcsm.12127","article-title":"A systematic review on the role of vitamins, minerals, proteins, and other supplements for the treatment of cachexia in cancer: a European palliative care research centre cachexia project","volume":"8","author":"Mochamat","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R39-20230926","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.clnu.2017.06.017","article-title":"ESPEN expert group recommendations for action against cancer-related malnutrition","volume":"36","author":"Arends","year":"2017","journal-title":"Clin Nutr"},{"key":"R40-20230926","first-page":"81","article-title":"Exercise recommendations for cancer-related fatigue, cognitive impairment, sleep problems, depression, pain, anxiety, and physical dysfunction: a review","volume":"8","author":"Mustian","year":"2012","journal-title":"Oncol Hematol Rev"},{"key":"R41-20230926","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s00520-015-2862-y","article-title":"Implementation of NCCN palliative care guidelines by member institutions","volume":"24","author":"Albizu-Rivera","year":"2016","journal-title":"Support Care Cancer"}],"container-title":["Current Opinion in Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01263393-201712000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T06:20:56Z","timestamp":1695709256000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01263393-201712000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0000000000000299","relation":{},"ISSN":["1751-4258","1751-4266"],"issn-type":[{"value":"1751-4258","type":"print"},{"value":"1751-4266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}